BioAtla (BCAB) Net Margin (2020 - 2026)

BioAtla's (BCAB) quarterly Net Margin came in at 3.57% in Q2 2026, up 100.78% quarter-over-quarter from 459.1% in Q4 2025.

Analysis

BioAtla (BCAB) Net Margin (2020 - 2026) Analysis & Trends

BioAtla (BCAB) has reported Net Margin for 5 consecutive years, with 3.57% the latest figure, recorded in Q2 2026.

For the quarter ending Q2 2026, Net Margin changed N/A year-over-year to 3.57%; the trailing twelve-month figure through Jun 2026 stood at 375.29% (up 18747.0% YoY), and the FY2025 full-year result was 2923.1%, down 228152.0% from the prior year.
Net Margin improved to 3.57% in Q2 2026 per BCAB's latest filing, from 459.1% in the prior quarter.
Across five years, Net Margin topped out at 3.57% in Q2 2026 and bottomed at 459.1% in Q4 2025.
Historically, Net Margin has averaged 183.92% across 3 years, with a median of 96.24% in 2024.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Amgen	206.64 Bn	192.65 Bn	7.24 Bn	23.62%
2	Gilead Sciences	179.82 Bn	176.65 Bn	6.22 Bn	-134.51%
3	Vertex Pharmaceuticals	131.16 Bn	123.31 Bn	2.84 Bn	32.99%
4	Regeneron Pharmaceuticals	81.67 Bn	73.67 Bn	3.93 Bn	30.23%
5	Argenx Se	60.28 Bn	55.09 Bn	1.37 Bn	31.16%
6	Moderna	53.91 Bn	48.77 Bn	52.00 Mn	-539.31%
7	Alnylam Pharmaceuticals	33.12 Bn	29.81 Bn	992.69 Mn	12.74%
8	Biogen	31.84 Bn	30.56 Bn	1.96 Bn	3.56%
9	Roivant Sciences	29.05 Bn	29.05 Bn	1.16 Mn	-20,152.98%
10	BioAtla	2.33 Mn	2.33 Mn	-	3.57%

Historic Data

Download Data